Prime Medicine Launches With $315m To Fund New Approach To Gene Editing
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.
You may also be interested in...
The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.